IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Acta Neuropathologica

• Publication date

  2015-02-21

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00401-015-1398-zPMID 25701198PMCID PMC4369189
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• TERT promoter mutations

  2017cited by this paper
• TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas.

  2015cited by this paper
• Mitotic Index is an Independent Predictor of Recurrence‐Free Survival in Meningioma

  2015cited by this paper
• Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors is associated with mutation of IDH.

  2014cited by this paper
• International Society of Neuropathology‐Haarlem Consensus Guidelines for Nervous System Tumor Classification and Grading

  2014cited by this paper
• Farewell to oligoastrocytoma: in situ molecular genetics favor classification as either oligodendroglioma or astrocytoma

  2014cited by this paper
• Spatial and temporal evolution of distal 10q deletion, a prognostically unfavorable event in diffuse low-grade gliomas

  2014influential reference
• Mutations in IDH1, IDH2, and in the TERT promoter define clinically distinct subgroups of adult malignant gliomas

  2014cited by this paper
• IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection.

  2014cited by this paper
• ATRX mRNA expression combined with IDH1/2 mutational status and Ki-67 expression refines the molecular classification of astrocytic tumors: evidence from the whole transcriptome sequencing of 169 samples

  2014cited by this paper
• TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal

  2013cited by this paper
• Adjuvant procarbazine, lomustine, and vincristine chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951.

  2013cited by this paper
• Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402.

  2013cited by this paper
• ATRX loss refines the classification of anaplastic gliomas and identifies a subgroup of IDH mutant astrocytic tumors with better prognosis

  2013cited by this paper
• The genetic landscape of anaplastic astrocytoma

  2013cited by this paper
• Combining two biomarkers, IDH1/2 mutations and 1p/19q codeletion, to stratify anaplastic oligodendroglioma in three groups: a single-center experience

  2013cited by this paper
• Intrinsic molecular subtypes of glioma are prognostic and predict benefit from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in anaplastic oligodendroglial brain tumors: a report from EORTC study 26951.

  2013cited by this paper
• Whole exome sequencing identifies ATRX mutation as a key molecular determinant in lower-grade glioma

  2012cited by this paper
• The prognostic value of IDH mutations and MGMT promoter status in secondary high-grade gliomas

  2012cited by this paper
• IDH Mutation and Neuroglial Developmental Features Define Clinically Distinct Subclasses of Lower Grade Diffuse Astrocytic Glioma

  2012influential reference
• No prognostic value of IDH1 mutations in a series of 100 WHO grade II astrocytomas

  2012cited by this paper
• Molecular classification of gliomas based on whole genome gene expression: a systematic report of 225 samples from the Chinese Glioma Cooperative Group.

  2012cited by this paper
• Clonal Analysis in Recurrent Astrocytic, Oligoastrocytic and Oligodendroglial Tumors Implicates IDH1- Mutation as Common Tumor Initiating Event

  2012cited by this paper
• IDH1/2 mutations in WHO grade II astrocytomas associated with localization and seizure as the initial symptom.

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• IDH1 mutation is sufficient to establish the glioma hypermethylator phenotype

  2012cited by this paper
• Significance of IDH mutations varies with tumor histology, grade, and genetics in Japanese glioma patients

  2012cited by this paper
• Molecular pathogenesis of IDH mutations in gliomas

  2012cited by this paper
• IDH mutations as an early and consistent marker in low-grade astrocytomas WHO grade II and their consecutive secondary high-grade gliomas

  2012cited by this paper
• Frequent ATRX, CIC, FUBP1 and IDH1 mutations refine the classification of malignant gliomas

  2012cited by this paper
• IDH1/2 mutation is a prognostic marker for survival and predicts response to chemotherapy for grade II gliomas concomitantly treated with radiation therapy.

  2012cited by this paper
• Temozolomide for low-grade gliomas: Predictive impact of 1p/19q loss on response and outcome

  2011cited by this paper
• Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin.

  2011cited by this paper
• Molecular Markers in Low-Grade Gliomas: Predictive or Prognostic?

  2011cited by this paper
• Central nervous system cancers.

  2011cited by this paper
• Evaluation of the proliferation markers Ki-67/MIB-1, mitosin, survivin, pHH3, and DNA topoisomerase IIα in human anaplastic astrocytomas - an immunohistochemical study

  2011cited by this paper
• All the 1p19q codeleted gliomas are mutated on IDH1 or IDH2

  2010cited by this paper
• Molecular diagnostics of gliomas: state of the art

  2010cited by this paper
• Interobserver variation of the histopathological diagnosis in clinical trials on glioma: a clinician’s perspective

  2010cited by this paper
• Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age: implications for classification of gliomas

  2010cited by this paper
• Absence of IDH mutation identifies a novel radiologic and molecular subtype of WHO grade II gliomas with dismal prognosis

  2010cited by this paper
• Identification of a CpG island methylator phenotype that defines a distinct subgroup of glioma.

  2010cited by this paper
• IDH1 or IDH2 mutations predict longer survival and response to temozolomide in low-grade gliomas

  2010cited by this paper
• IDH1 and IDH2 Mutations Are Prognostic but not Predictive for Outcome in Anaplastic Oligodendroglial Tumors: A Report of the European Organization for Research and Treatment of Cancer Brain Tumor Group

  2010cited by this paper
• Abstract 808: Intrinsic gene expression profiles of gliomas are a better predictor of survival than histology

  2010cited by this paper
• Molecular classification of low-grade diffuse gliomas.

  2010cited by this paper
• High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors

  2010cited by this paper
• IDH 1 and IDH 2 Mutations in Gliomas

  2009cited by this paper
• NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.

  2009cited by this paper
• Analysis of IDH1 and IDH2 mutations in Japanese glioma patients

  2009cited by this paper
• Operative techniques for gliomas and the value of extent of resection

  2009cited by this paper
• IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas.

  2009cited by this paper
• IDH1 and IDH2 mutations in gliomas.

  2009cited by this paper
• Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.

  2009cited by this paper
• IDH1 Mutations as Molecular Signature and Predictive Factor of Secondary Glioblastomas

  2009cited by this paper
• Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma.

  2008cited by this paper
• Comprehensive genomic characterization defines human glioblastoma genes and core pathways

  2008cited by this paper
• Role of extent of resection in the long-term outcome of low-grade hemispheric gliomas.

  2008cited by this paper
• An Integrated Genomic Analysis of Human Glioblastoma Multiforme

  2008cited by this paper
• Preoperative prognostic classification system for hemispheric low-grade gliomas in adults.

  2008cited by this paper
• Temozolomide for low-grade gliomas

  2007cited by this paper
• Panel Review of Anaplastic Oligodendroglioma From European Organization for Research and Treatment of Cancer Trial 26951: Assessment of Consensus in Diagnosis, Influence of 1p/19q Loss, and Correlations With Outcome

  2007cited by this paper
• Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma.

  2007cited by this paper
• The 2007 WHO Classification of Tumours of the Central Nervous System

  2007cited by this paper
• Phase III trial of chemotherapy plus radiotherapy compared with radiotherapy alone for pure and mixed anaplastic oligodendroglioma: Intergroup Radiation Therapy Oncology Group Trial 9402.

  2006cited by this paper
• Adjuvant procarbazine, lomustine, and vincristine improves progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a randomized European Organisation for Research and Treatment of Cancer phase III trial.

  2006cited by this paper
• Assessment and Prognostic Significance of Mitotic Index Using the Mitosis Marker Phospho-histone H3 in Low and Intermediate-grade Infiltrating Astrocytomas

  2006influential reference
• Apoptosis and Proliferation Markers in Diffusely Infiltrating Astrocytomas: Profiling of 17 Molecules

  2006cited by this paper
• Central nervous system cancers.

  2005cited by this paper
• The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors

  2005cited by this paper
• Prognostic factors for survival in adult patients with cerebral low-grade glioma.

  2002cited by this paper
• Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay.

  2001cited by this paper
• Pretreatment factors predict overall survival for patients with low-grade glioma: a recursive partitioning analysis.

  1999cited by this paper
• Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas.

  1998cited by this paper
• Chromatin Condensation Is Not Associated with Apoptosis*

  1998cited by this paper
• Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas

  1997cited by this paper
• Mitosis-specific phosphorylation of histone H3 initiates primarily within pericentromeric heterochromatin during G2 and spreads in an ordered fashion coincident with mitotic chromosome condensation

  1997cited by this paper
• Supratentorial low-grade glioma in adults: an analysis of prognostic factors and timing of radiation.

  1997cited by this paper
• Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p.

  1994cited by this paper

• Customized SAM-Med3D with multi-view adapter and T2-FLAIR mismatch features for glioma IDH genotyping and grading

  2026cites this paper
• Association of a diffuse phenotype on MRI with shorter overall survival in patients with astrocytoma CNS WHO grades 2 and 3.

  2026cites this paper
• Oligodendrogliomas: findings after classifying the same cohort using pre- and post-World Health Organization (WHO) 2021 criteria

  2025influential citation
• Histopathological grading affects survival in patients with isocitrate dehydrogenase-wildtype gliomas

  2025cites this paper
• Restoring epigenetic balance for glioma: Targeting IDH1_R132H with phytocompounds and tracking their efficacy under various pH conditions.

  2025cites this paper
• Case report: Pseudoprogression mimicking neoplastic recurrence three months after completion of proton beam therapy for an IDH-mutant astrocytoma CNS WHO grade 3

  2025cites this paper
• Expanded Use of Vorasidenib in Non-Enhancing Recurrent CNS WHO Grade 3 Oligodendroglioma

  2025cites this paper
• Cell Image Classification with Polygon-Guided Extraction for Glioma Mitosis Detection

  2025cites this paper
• MYCN amplification defines an aggressive phenotype in IDH‐mutant gliomas

  2025cites this paper
• Clinical and neuropathological criteria for distinguishing between IDH-mutant astrocytomas of WHO grade 2 and 3

  2025cites this paper
• Revisiting prognosis of oligodendroglioma patients in the 2021 WHO classification: incremental value of imaging features

  2025cites this paper
• Diagnostic and prognostic potential of cell-free RNAs in cerebrospinal fluid and plasma for brain tumors

  2025cites this paper
• Unlocking new horizons: advances in treating IDH-mutant, 1p/19q-codeleted oligodendrogliomas

  2025cites this paper
• Molecular alterations in IDH-mutant astrocytoma: A multi-institutional retrospective study

  2025influential citation
• Integrating Rapid Evaporative Ionization Mass Spectrometry Classification with Matrix-Assisted Laser Desorption Ionization Mass Spectrometry Imaging and Liquid Chromatography-Tandem Mass Spectrometry to Unveil Glioblastoma Overall Survival Prediction

  2025cites this paper
• Management and survival trends for diffuse gliomas diagnosed at a single neurooncology center in China during 2000 to 2020

  2025cites this paper
• IDH mutation and MGMT methylation status in glioblastoma and other gliomas patients: a Russian retrospective cohort study

  2025cites this paper
• Survival outcomes associated with antidepressant use in glioblastoma: a cohort study

  2025cites this paper
• Interpretable artificial intelligence based determination of glioma IDH mutation status directly from histology slides

  2025cites this paper
• Survival prediction with radiomics for patients with IDH mutated lower-grade glioma

  2025cites this paper
• Left-hemisphere glioma drives systematic patterns of contralesional functional connectivity

  2025cites this paper
• Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors

  2025cites this paper
• Prognostic stratification of newly diagnosed IDH-mutant gliomas by [18F]fluoroethyltyrosine and [11C]methionine PET - a retrospective, bicentric cohort study.

  2025cites this paper
• MRI-based prediction of DNA methylation grade in IDH-mutant astrocytomas using qualitative imaging features and tumor volumetrics

  2025cites this paper
• Survival Outcomes Associated with Antidepressant Use in Glioblastoma: A Cohort Study

  2025cites this paper
• Oncogenic role of IDH1 RNA-binding activity in glioblastoma progression.

  2025cites this paper
• Anatomical and subcortical invasiveness in diffuse low-grade astrocytomas differ between IDH status and provide prognostic information

  2024cites this paper
• Beyond invasive biopsies: using VASARI MRI features to predict grade and molecular parameters in gliomas

  2024cites this paper
• A systematic review and meta-analysis informing the role of adjuvant radiotherapy (RT) in Grade 2 and 3 oligodendroglioma.

  2024cites this paper
• Endothelial cell ferroptosis influences IDH wild-type glioblastoma growth in recurrent glioblastoma multiforme patients

  2024cites this paper
• The Role of Mutant IDH Inhibitors in the Treatment of Glioma

  2024cites this paper
• A Study on Prognosis of Diffuse Glioma Based on Clinical Factors and Magnetic Resonance Imaging Radiomics.

  2024cites this paper
• T2-FLAIR mismatch sign predicts DNA methylation subclass and CDKN2A/B status in IDH-mutant astrocytomas.

  2024cites this paper
• VASARI 2.0: a new updated MRI VASARI lexicon to predict grading and IDH status in brain glioma

  2024cites this paper
• Epigenetic landscape reorganisation and reactivation of embryonic development genes are associated with malignancy in IDH-mutant astrocytoma

  2024cites this paper
• Brainstem Gliomas With Isocitrate Dehydrogenase Mutation: Natural History, Clinical-Radiological Features, Management Strategy, and Long-Term Outcome

  2024influential citation
• Role of the tumor board when prescribing mutant isocitrate dehydrogenase inhibitors to patients with isocitrate dehydrogenase-mutant glioma.

  2024cites this paper
• Development of an m6A-Related lncRNAs Signature Predicts Tumor Stemness and Prognosis for Low-Grade Glioma Patients

  2024cites this paper
• Improved prognostic stratification of patients with isocitrate dehydrogenase-mutant astrocytoma

  2024cites this paper
• Prognostic value of DNA methylation subclassification, aneuploidy, and CDKN2A/B homozygous deletion in predicting clinical outcome of IDH mutant astrocytomas.

  2024cites this paper
• New Glioma Classification and Its Impact on Treatment Strategy

  2024cites this paper
• Who will benefit from vorasidenib? Review of data from the literature and open questions.

  2024cites this paper
• Comprehensive multicentre retrospective analysis for predicting isocitrate dehydrogenase‐mutant lower‐grade gliomas

  2024cites this paper
• Complement and coagulation cascades are associated with prognosis and the immune microenvironment of lower-grade glioma

  2024cites this paper
• A novel grading system combining histological grade and CDKN2A homozygous and hemizygous deletion to predict prognosis in IDH-mutant astrocytoma.

  2024cites this paper
• Volumetric Response and Survival of Patients With Bulky IDH-Mutated Grade 3 Glioma Managed With FET-FDG-Guided Integrated Boost IMRT.

  2024cites this paper
• Ready to INDIGO: Vorasidenib Ushers in the Era of Isocitrate Dehydrogenase Inhibition in Low-Grade Glioma.

  2024cites this paper
• Watch-and-wait approach versus adjuvant treatment after radical awake resection in selected adult-type grade 3 gliomas, isocitrate dehydrogenase mutant: A case-matched cohort

  2024cites this paper
• Treatment Options for IDH-Mutant Malignant Gliomas

  2024cites this paper
• Improved immunostaining of nanostructures and cells in human brain specimens through expansion-mediated protein decrowding

  2024cites this paper
• Molecular Pathology of Gliomas.

  2024cites this paper
• Early progressive disease within 2 years in isocitrate dehydrogenase (IDH)-mutant astrocytoma may indicate radiation necrosis.

  2024cites this paper
• Reappraisal of prognostic factors in CNS WHO grade 3 oligodendrogliomas IDH-mutant and 1p/19q co-deleted: lessons from the French POLA cohort.

  2024cites this paper
• Prognostic Impact of TERT Promoter Mutations in Adult-Type Diffuse Gliomas Based on WHO2021 Criteria

  2024cites this paper
• Genomic Profiling in Glioma Patients to Explore Clinically Relevant Markers

  2024cites this paper
• Differences in the prognostic role of age, extent of resection and tumor grade between astrocytoma IDHmt and oligodendroglioma: a single center cohort study.

  2024cites this paper
• The biological significance of tumor grade, age, enhancement, and extent of resection in IDH-mutant gliomas: How should they inform treatment decisions in the era of IDH inhibitors?

  2024cites this paper
• Single-Voxel MR Spectroscopy of Gliomas with s-LASER at 7T

  2023cites this paper
• Delineation of Grade II and III Gliomas Investigated by 7T MRI: An Inter-Observer Pilot Study

  2023cites this paper
• A threshold for mitotic activity and post‐surgical residual volume defines distinct prognostic groups for astrocytoma IDH‐mutant

  2023cites this paper
• CDKN2A/B Homozygous Deletions in Astrocytomas: A Literature Review

  2023cites this paper
• Photoacoustic Chemical Imaging Sodium Nano-Sensor Utilizing a Solvatochromic Dye Transducer for In Vivo Application

  2023cites this paper
• Central Nervous System Cancers, Version 2.2022 Featured Updates to the NCCN Guidelines

  2023cites this paper
• Morphogenetic characteristics of glial tumors in adults per the WHO classifications of 2007, 2016, 2021. Changes in the classifications and their significance for clinical practice

  2023cites this paper
• PI3K signaling pathways as a molecular target for Glioblastoma Multiforme.

  2023cites this paper
• Serum lipids concentration on prognosis of high-grade glioma

  2023cites this paper
• Detection of diagnostic and prognostic methylation-based signatures in liquid biopsy specimens from patients with meningiomas

  2023cites this paper
• Treating oligodendroglioma – An analysis of a homogeneous 1p/19q-codeleted and isocitrate dehydrogenase-mutant patient cohort

  2023cites this paper
• Same but different. Incidental and symptomatic lower grade gliomas show differences in molecular features and survival

  2023cites this paper
• [A Dual-Aware deep learning framework for identification of glioma isocitrate dehydrogenase genotype using magnetic resonance amide proton transfer modalities].

  2023cites this paper
• Mitotic index is (still) important for grading IDH-mutant astrocytoma.

  2023cites this paper
• Qualitative and Quantitative Magnetic Resonance Imaging Phenotypes May Predict CDKN2A/B Homozygous Deletion Status in Isocitrate Dehydrogenase-Mutant Astrocytomas: A Multicenter Study

  2023cites this paper
• Updates on the WHO diagnosis of IDH-mutant glioma

  2023cites this paper
• NCCN Guidelines® Insights: Central Nervous System Cancers, Version 2.2022.

  2023cites this paper
• Apparent Diffusion Coefficient as Imaging Biomarker for Identifying IDH Mutation, 1p19q Codeletion, and MGMT Promoter Methylation Status in Patients With Glioma

  2023cites this paper
• Investigating survival, quality of life and cognition in PROton versus photon therapy for IDH-mutated diffuse grade 2 and 3 GLIOmas (PRO-GLIO): a randomised controlled trial in Norway and Sweden

  2023cites this paper
• Events in CNS Tumor Pathology Post-2016 WHO CNS: cIMPACT-NOW Updates and Other Advancements: A Comprehensive Review Plus a Summary of the Salient Features of 2021 WHO CNS 5

  2023cites this paper
• Isocitrate-dehydrogenase-mutant lower grade glioma in elderly patients: treatment and outcome in a molecularly characterized contemporary cohort

  2023cites this paper
• Cyclin-Dependent Kinase Inhibitor 2A/B Homozygous Deletion Prediction and Survival Analysis

  2023cites this paper
• Diffusion Weighted Imaging in Gliomas: A Histogram-Based Approach for Tumor Characterization

  2022cites this paper
• [Development and Evaluation of Prognostic Nomogram Model for Adult Ventricle Glioma Patients].

  2022cites this paper
• Adding radiomics to the 2021 WHO updates may improve prognostic prediction for current IDH-wildtype histological lower-grade gliomas with known EGFR amplification and TERT promoter mutation status

  2022cites this paper
• Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas

  2022cites this paper
• Molecular Aberrations Stratify Grade 2 Astrocytomas Into Several Rare Entities: Prognostic and Therapeutic Implications

  2022cites this paper
• Current Considerations in the Treatment of Grade 3 Gliomas

  2022cites this paper
• Grading of IDH-mutant astrocytoma using diffusion, susceptibility and perfusion-weighted imaging

  2022cites this paper
• A Novel TNFSF-Based Signature Predicts the Prognosis and Immunosuppressive Status of Lower-Grade Glioma

  2022cites this paper
• PDPN marks a subset of aggressive and radiation-resistant glioblastoma cells

  2022cites this paper
• Executive summary of american radium society's appropriate use criteria for the postoperative management of lower grade gliomas.

  2022cites this paper
• Gliomas: Genetic alterations, mechanisms of metastasis, recurrence, drug resistance, and recent trends in molecular therapeutic options.

  2022cites this paper
• Laser Interstitial Thermal Therapy in Grade 2/3 IDH1/2 Mutant Gliomas: A Preliminary Report and Literature Review

  2022cites this paper
• Radiation Therapy for IDH-Mutant Grade 2 and Grade 3 Diffuse Glioma: An ASTRO Clinical Practice Guideline.

  2022cites this paper
• Molecular Biomarker Testing for the Diagnosis of Diffuse Gliomas.

  2022cites this paper
• Molecular Imaging of Brain Tumors and Drug Delivery Using CEST MRI: Promises and Challenges

  2022cites this paper
• The Clinical Frailty Scale as predictor of overall survival after resection of high-grade glioma

  2022cites this paper
• Duchenne muscular dystrophy gene expression is an independent prognostic marker for IDH mutant low-grade glioma

  2022cites this paper
• Challenges of imaging interpretation to predict oligodendroglioma grade: a report from the Neuro-Oncology Branch

  2022cites this paper
• Distinct metabolic hallmarks of WHO classified adult glioma subtypes

  2022cites this paper
• The impact of resection in IDH-mutant WHO grade 2 gliomas: a retrospective population-based parallel cohort study.

  2022cites this paper
• Large tumour volume reduction of IDH-mutated anaplastic glioma involving the insular region following radiotherapy

  2022cites this paper